Delayed profound thrombocytopenia after abciximab administration for coronary stenting in acute coronary syndrome. Case reports and review of the literature.
Profound thrombocytopenia occurring 1 week after drug administration is a seldom described, self-limiting and mostly uneventful immune reaction to abciximab. Quick differential diagnosis is essential, since other forms of thrombocytopenia associated with concomitant antithrombotic therapies may be much more severe and require prompt treatment. Awareness of this reaction may avoid unnecessary and risky discontinuation of other antiplatelet therapies in the critical phase after coronary stenting.
Trapolin
Gaia
G
A De Gasperis Cardiovascular Department,Niguarda Ca' Granda Hospital, Milan, Italy.
Savonitto
Stefano
S
Merlini
Piera Angelica
PA
Caimi
Maria Teresa
MT
Klugmann
Silvio
S
D000077284:Abciximab; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation / Q000379:methods; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D017023:Coronary Angiography; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods; D010976:Platelet Count; D018570:Risk Assessment; D012720:Severity of Illness Index; D015607:Stents / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab